Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: Burkitt Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Welcome to The Burkitt Lymphoma Channel

VJHemOnc brings you the newest advances in the field of Burkitt lymphoma, with video interviews, podcasts, and roundtable discussions from the experts. The Burkitt Lymphoma Channel provides coverage from key congresses with insightful commentary on the latest developments in diagnosing Burkitt lymphoma, novel combination and CAR-T therapies, and more.

Expanding the CAR platform for NHL 11:30
Expanding the CAR platform for NHL
Catherine Bollard et al. • 28 Sep 2025
Insights into the management of Burkitt lymphoma: the need to improve frontline treatment 1:19
Insights into the management of Burkitt lymphoma: the need to improve frontline treatment
Ariela Noy • 3 Sep 2025
Challenges associated with double-hit R/R Burkitt lymphoma & novel therapies being explored 1:24
Challenges associated with double-hit R/R Burkitt lymphoma & novel therapies being explored
Ariela Noy • 3 Sep 2025
The outcomes of autoSCT and alloSCT in R/R Burkitt lymphoma: an analysis of EBMT Registry data 2:37
The outcomes of autoSCT and alloSCT in R/R Burkitt lymphoma: an analysis of EBMT Registry data
Lorenz Thurner • 11 Jun 2025
A novel approach: targeting MYC for the treatment of acute leukemias 4:39
A novel approach: targeting MYC for the treatment of acute leukemias
Michael Andreeff • 18 Mar 2025
AI-REAL: improving diagnosis and treatment in EBV-associated Burkitt lymphoma
Anna Schuh • 25 Mar 2024
Facilitating diagnosis of Burkitt lymphoma in children in Uganda and Tanzania 3:04
Facilitating diagnosis of Burkitt lymphoma in children in Uganda and Tanzania
Anna Schuh • 7 Oct 2023
Unmet needs in Burkitt lymphoma: diagnosis and treatment 1:20
Unmet needs in Burkitt lymphoma: diagnosis and treatment
Sam Mbulaiteye • 16 Jun 2023
The International Burkitt Lymphoma Network: a valuable opportunity for collaboration 0:53
The International Burkitt Lymphoma Network: a valuable opportunity for collaboration
Sam Mbulaiteye • 16 Jun 2023
LBA: genome-wide association study of childhood Burkitt lymphoma in East Africa 2:07
LBA: genome-wide association study of childhood Burkitt lymphoma in East Africa
Sam Mbulaiteye • 16 Jun 2023
Efficacy of varnimcabtagene autoleucel in patients with R/R BCL with no indication for CAR-T therapy 2:25
Efficacy of varnimcabtagene autoleucel in patients with R/R BCL with no indication for CAR-T therapy
Valentín Ortiz-Maldonado • 8 Jun 2023
BURKIMAB14: dose reduction of chemotherapy in young adults with Burkitt lymphoma 1:25
BURKIMAB14: dose reduction of chemotherapy in young adults with Burkitt lymphoma
Josep-Maria Ribera • 9 Jun 2023
An analysis of the risk factors associated with disease progression in patients with BL 3:10
An analysis of the risk factors associated with disease progression in patients with BL
Mark Roschewski • 14 Dec 2021
Treating lymphoma in the developing world 4:13
Treating lymphoma in the developing world
Franco Cavalli • 24 Jun 2021
Diagnosing and treating NHL in teenagers and young adults 6:46
Diagnosing and treating NHL in teenagers and young adults
Robert Carr • 22 Jun 2021
Developing the novel Burkitt Lymphoma International Prognostic Index 3:16
Developing the novel Burkitt Lymphoma International Prognostic Index
Adam Olszewski • 8 Dec 2020

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

Diamond Supporter

AstraZeneca

Gold Supporter

BMS Johnson & Johnson

Silver Supporter

Takeda

Bronze Supporter

Galapagos

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals